company background image
DNA

Ginkgo Bioworks Holdings NYSE:DNA Stock Report

Last Price

US$1.82

Market Cap

US$3.1b

7D

-8.5%

1Y

-81.9%

Updated

10 Dec, 2022

Data

Company Financials +
DNA fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance0/6
Financial Health5/6
Dividends0/6

DNA Stock Overview

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming.

Ginkgo Bioworks Holdings, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Ginkgo Bioworks Holdings
Historical stock prices
Current Share PriceUS$1.82
52 Week HighUS$11.66
52 Week LowUS$1.64
Beta0
1 Month Change-20.87%
3 Month Change-38.10%
1 Year Change-81.93%
3 Year Changen/a
5 Year Changen/a
Change since IPO-82.02%

Recent News & Updates

Ginkgo Bioworks launches Ginkgo Enzyme Services

Dec 08

Recent updates

Is There An Opportunity With Ginkgo Bioworks Holdings, Inc.'s (NYSE:DNA) 50% Undervaluation?

Aug 26
Is There An Opportunity With Ginkgo Bioworks Holdings, Inc.'s (NYSE:DNA) 50% Undervaluation?

Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Just Reported, And Analysts Assigned A US$10.14 Price Target

Apr 01
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Just Reported, And Analysts Assigned A US$10.14 Price Target

Shareholder Returns

DNAUS ChemicalsUS Market
7D-8.5%-1.7%-2.8%
1Y-81.9%-8.3%-19.6%

Return vs Industry: DNA underperformed the US Chemicals industry which returned -8.3% over the past year.

Return vs Market: DNA underperformed the US Market which returned -19.6% over the past year.

Price Volatility

Is DNA's price volatile compared to industry and market?
DNA volatility
DNA Average Weekly Movement13.5%
Chemicals Industry Average Movement6.8%
Market Average Movement7.4%
10% most volatile stocks in US Market15.5%
10% least volatile stocks in US Market3.3%

Stable Share Price: DNA is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 13% a week.

Volatility Over Time: DNA's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
2008641Jason Kellyhttps://www.ginkgobioworks.com

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals.

Ginkgo Bioworks Holdings, Inc. Fundamentals Summary

How do Ginkgo Bioworks Holdings's earnings and revenue compare to its market cap?
DNA fundamental statistics
Market CapUS$3.08b
Earnings (TTM)-US$3.53b
Revenue (TTM)US$527.92m

5.8x

P/S Ratio

-0.9x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
DNA income statement (TTM)
RevenueUS$527.92m
Cost of RevenueUS$240.58m
Gross ProfitUS$287.34m
Other ExpensesUS$3.82b
Earnings-US$3.53b

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-2.09
Gross Margin54.43%
Net Profit Margin-668.49%
Debt/Equity Ratio0%

How did DNA perform over the long term?

See historical performance and comparison